|
Market Closed -
Nasdaq
16:00:00 2026-09-22 EDT
|
After hours 17:09:17 | |||
| 33.51 USD | -11.56% |
|
33.65 | +0.42% |
| 03:02pm | Top Midday Decliners | MT |
| 02:51pm | Celldex Therapeutics, Inc. - Special Call |
Company Valuation: Celldex Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,803 | 2,099 | 2,169 | 1,677 | 1,805 | 2,975 | - | - |
| Change | - | 16.42% | 3.32% | -22.7% | 7.65% | 64.87% | - | - |
| Enterprise Value (EV) 1 | 1,395 | 1,794 | 1,745 | 951.2 | 1,286 | 2,313 | 2,341 | 2,401 |
| Change | - | 28.64% | -2.73% | -45.5% | 35.21% | 79.85% | 1.2% | 2.55% |
| P/E | -23.6x | -18.6x | -13.6x | -10.3x | -6.96x | -9.03x | -8.9x | -10.9x |
| PBR | - | - | - | 2.25x | 3.43x | 5.02x | 4.91x | 5.48x |
| PEG | - | -0.4x | -0.6x | 0.6x | -0.1x | -1.19x | -6.02x | 0.6x |
| Capitalization / Revenue | 388x | 891x | 315x | 239x | 1,168x | 1,642x | 262x | 21.2x |
| EV / Revenue | 300x | 761x | 254x | 136x | 832x | 1,276x | 206x | 17.1x |
| EV / EBITDA | - | - | -11.3x | -4.96x | -4.53x | -7.3x | -7.21x | -10.1x |
| EV / EBIT | -19.6x | -15.6x | -12.3x | -4.88x | -4.48x | -6.85x | -6.32x | -7.86x |
| EV / FCF | -22.4x | -17x | -16x | -5.96x | -6.02x | -8.41x | -9.77x | -10.7x |
| FCF Yield | -4.46% | -5.88% | -6.25% | -16.8% | -16.6% | -11.9% | -10.2% | -9.33% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.64 | -2.4 | -2.92 | -2.45 | -3.9 | -4.196 | -4.258 | -3.473 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.651 | 2.357 | 6.883 | 7.02 | 1.545 | 1.812 | 11.38 | 140.4 |
| EBITDA 1 | - | - | -154.5 | -191.9 | -284 | -316.9 | -324.8 | -237.2 |
| EBIT 1 | -71.24 | -115.2 | -142 | -195.1 | -287.4 | -337.6 | -370.2 | -305.3 |
| Net income 1 | -70.51 | -112.3 | -141.4 | -157.9 | -258.8 | -319.2 | -360.9 | -324.2 |
| Net Debt 1 | -408.2 | -305 | -423.6 | -725.3 | -518.6 | -662.3 | -634.5 | -574.8 |
| Reference price 2 | 38.64 | 44.57 | 39.66 | 25.27 | 27.16 | 37.89 | 37.89 | 37.89 |
| Nbr of stocks (in thousands) | 46,664 | 47,100 | 54,689 | 66,344 | 66,449 | 78,530 | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 2/26/24 | 2/27/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.03x | 1138.82x | -7.3x | -.--% | 2.98B | |
| 32.07x | 5.77x | 17.28x | 1.01% | 46.68B | |
| 34.76x | 3.35x | 14.44x | -.--% | 44.42B | |
| -19.81x | 213.44x | -21.53x | -.--% | 41.32B | |
| 47.9x | 5.56x | 30.41x | -.--% | 41.58B | |
| 27.45x | 7.91x | 20.36x | 0.41% | 30.14B | |
| 35.5x | 5.83x | 26.48x | -.--% | 17.42B | |
| 26.02x | 2.23x | 9.67x | 1.03% | 15.54B | |
| -56.03x | 9.2x | 224.52x | -.--% | 14.08B | |
| Average | 13.20x | 154.68x | 34.92x | 0.27% | 28.24B | |
| Weighted average by Cap. | 20.65x | 52.57x | 24.34x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CLDX Stock
- Valuation Celldex Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
